WallStSmart

Adagio Medical Holdings, Inc Common Stock (ADGM)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 15325447% more annual revenue ($21.00B vs $137,000). BSX leads profitability with a 17.5% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 72/100 (B).

ADGM

Hold

36

out of 100

Grade: F

Growth: 6.3Profit: 3.0Value: 5.0Quality: 3.5
Piotroski: 2/9Altman Z: -4.22

BSX

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 5/9Altman Z: 1.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ADGM.

BSXSignificantly Overvalued (-22.3%)

Margin of Safety

-22.3%

Fair Value

$39.03

Current Price

$49.31

$10.28 premium

UndervaluedFair: $39.03Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADGM2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
75.6%10/10

Revenue surging 75.6% year-over-year

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$71.14B9/10

Large-cap with strong market position

PEG RatioValuation
0.678/10

Growing faster than its price suggests

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Areas to Watch

ADGM4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$10.22M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ADGM

The strongest argument for ADGM centers on Revenue Growth, Price/Book. Revenue growth of 75.6% demonstrates continued momentum.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Price/Book. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.67 suggests the stock is reasonably priced for its growth.

Bear Case : ADGM

The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 4.21 is elevated, increasing financial risk.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Key Dynamics to Monitor

ADGM profiles as a hypergrowth stock while BSX is a mature play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.57 — expect wider price swings.

ADGM is growing revenue faster at 75.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (72/100 vs 36/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Adagio Medical Holdings, Inc Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing the treatment of cardiac arrhythmias through advanced medical technologies. Utilizing its proprietary platform, the company is spearheading the development of targeted ablation techniques that address significant unmet needs in the electrophysiology sector. Supported by a robust product pipeline and a seasoned leadership team, Adagio represents an attractive investment opportunity for institutional investors seeking growth in the healthcare space while contributing to improved outcomes in cardiac patient care.

Visit Website →

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?